Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Abstract

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).

Keywords

Affiliated Institutions

• Peter MacCallum Cancer Centre AU
• Aichi Cancer Center JP
• The University of Melbourne AU
• University Hospital Heidelberg DE
• Institut Curie FR
• Queen Mary University of London GB
• Bloomberg (United States) US
• Dana-Farber Cancer Institute US
• New York University US
• Pontifícia Universidade Católica do Rio Grande do Sul BR
• Universidade de São Paulo BR
• University of California, San Francisco US
• Florida Cancer Specialists & Research Institute US
• Hospital São Lucas da PUCRS BR
• Heidelberg University DE
• Seoul National University Hospital KR
• Roche (Switzerland) CH

Related Publications